Week in Review: Collaboration Brings R&D Opportunities

Week in Review: Collaboration Brings R&D Opportunities

01.25.13 | By

Many of The Catalyst posts this month have discussed different aspects of innovation, and this week, we focused on one of the most important elements: research and development. Innovation is the catalyst for researching and developing lifesaving new treatments that coupled with the right partnerships and idea sharing opportunities is key to ensuring long-term success.

Competitors and Partners

Although pharmaceutical companies are often viewed as competitors, many of their scientists are collaborating to help patients suffering from diabetes. Dr. Elisabeth Bjork, AstraZeneca Vice President and Head of Cardiovascular and Gastrointestinal Global Medicines Development, contributed a guest post in which she discussed advancements in Type 2 diabetes research and the partnerships they are helping them get there, including:

  • A Bristol-Myers Squibb partnership that began in 2007 and researches, develops and commercializes products that represent a new version of treatment for Type 2 diabetes
  • A worldwide exclusive licensing agreement with Ardelyx for a research program that may help treat end-stage renal disease and chronic kidney disease, which are serious complications of diabetes

Public-Private Partnerships

Karl Uhlendorf authored a piece on Alzheimer's that addressed studies under the Alzheimer's Disease Cooperative Study that reflects the breadth of emerging ideas and the range of stakeholders, including government, private companies and academia, that are working together. The four studies will address:

  • Secondary prevention in a pre-symptomatic population
  • Use of aerobic exercise in older adults with mild cognitive impairment
  • Treatment of disruptive agitation with a generic alpha blocker medication for frail and elderly people
  • Long-term evaluation of cerebrospinal fluid and blood plasma biomarkers used to better understand drugs' mechanisms

Research and development is a long process, and as these partnerships show, working together to maximizing resources and ideas is often the best solution. We look forward to sharing more of these stories that articulate how the industry is working together and encourage you to leave your comments and check The Catalyst regularly for more news and industry updates.

More On PhRMA — powered by PhRMApedia


Cost in Context